Insider Selling: Derma Sciences Insider Sells 300,000 Shares of Stock (DSCI)
Derma Sciences (NASDAQ:DSCI) Insider Ra Capital Management, Llc sold 300,000 shares of Derma Sciences stock on the open market in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $11.83, for a total value of $3,549,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
DSCI has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Derma Sciences from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, January 1st. They now have a $12.50 price target on the stock. Separately, analysts at Sidoti initiated coverage on shares of Derma Sciences in a research note to investors on Thursday, December 19th. They set a “neutral” rating on the stock. Finally, analysts at TheStreet downgraded shares of Derma Sciences to a “sell” rating in a research note to investors on Friday, December 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Derma Sciences has a consensus rating of “Hold” and an average price target of $15.75.
Shares of Derma Sciences (NASDAQ:DSCI) traded up 0.94% during mid-day trading on Monday, hitting $11.81. 378,365 shares of the company’s stock traded hands. Derma Sciences has a 52-week low of $9.93 and a 52-week high of $15.45. The stock’s 50-day moving average is $11.31 and its 200-day moving average is $12.67. The company’s market cap is $204.1 million.
Derma Sciences (NASDAQ:DSCI) last announced its earnings results on Wednesday, November 13th. The company reported ($0.29) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.44) by $0.15. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $21.96 million. During the same quarter in the prior year, the company posted ($0.24) earnings per share. Analysts expect that Derma Sciences will post $-1.47 EPS for the current fiscal year.
Derma Sciences, Inc (NASDAQ:DSCI) is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.